The potential for treating hypertension with an injectable drug based on small interfering ribonucleic acid called zilebesiran is being actively studied, and a single subcutaneous administration of zilebesiran resulted in a significant reduction in blood pressure, with the effect lasting for up to 6 months.
Abstract
Inadequate blood pressure control is one of the main causes of cardiovascular complications. This problem remains pressing, in part due to low adherence to therapy associated with complex regimens. This has led to attempts to find new solutions, including the development of agents that do not require frequent administration and can be used to enhance the antihypertensive effect in addition to existing oral medications. Currently, the potential for treating hypertension with an injectable drug based on small interfering ribonucleic acid called zilebesiran is being actively studied. Its antihypertensive effect is associated with the suppression of hepatic angiotensinogen production and a corresponding reduction in angiotensin II levels. In a clinical trial, a single subcutaneous administration of zilebesiran resulted in a significant reduction in blood pressure, with the effect lasting for up to 6 months. This article reviews the literature on this new antihypertensive drug.
This review provides a general overview of the physiological effects and pharmacokinetic properties that affect the absorption, distribution, metabolism, and elimination of recently developed antihypertensive drugs, such as fimasartan, azilsartan, zilebesiran, aprocitentan, and esaxerenone. It provides an opportunity t...
Pritesh Mahajan, Ashish Pagar, Kajal Baviskar et al.· Current hypertension reviews· 0 citations
This publication is devoted to a comparative analysis of the hemostasiological effects of different classes of glucose-lowering agents in patients with type 2 diabetes, with a particular focus on the molecular and cellular mechanisms underlying their impact on coagulation status. It has been demonstrated that the influ...
L. A. Asadova, M. Gurba, F. C. Alieva et al.· Meditsinskiy sovet = Medical...· 0 citations
The burden of lipid metabolism disorders is significant and high. According to the ESSE-RF 3 population-based study conducted in 15 regions of the Russian Federation from 2020 to 2022, which included 28,731 men and women aged 35‒74 years, the prevalence of hypercholesterolemia was 58.8%, and only 7.6% were receiving li...
T. Kolmakova, M. Ezhov· Meditsinskiy sovet = Medical...· 0 citations
Telmisartan is a benzimidazole derivative and a well‐known drug to treat hypertension. This is an angiotensin II receptor blocker (ARB) which helps to relax blood vessels. Studies have shown that telmisartan is effective in reducing cardiovascular disease, with a safety and efficacy profile. This review paper provides...
Megha, Richa Srivastava, Ram Singh· Chemistry and Biodiversity· 0 citations
The aim of this work is to critically evaluate the benefits and risks of zilebesiran. A comprehensive literature search was conducted in PubMed and Google Scholar databases to identify relevant studies on zilebesiran and other small-interfering RNA (siRNA)-based therapies for hypertension. The search covered publicatio...
Jerzy Głuszek, T. Kosicka· Wiadomosci lekarskie· 0 citations
A man in his early 60s with previously well-controlled hypertension developed sudden deterioration in blood pressure control 2 weeks after starting isoniazid-rifampin therapy for latent tuberculosis infection. His blood pressure had previously been stable on an angiotensin receptor blocker and a calcium channel blocker...
J. Park· BMJ Case Reports· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
